Description
Emapalumab (IFNG ) Antibody, Monoclonal | 10-806 | Gentaur UK, US & Europe Distribution
Host: N/A
Reactivity: N/A
Homology: N/A
Immunogen: Homo sapiens / IFNG [Homo sapiens]
Research Area: Drug Analogues
Tested Application: N/A
Application: N/A
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: >95%
Clonality: Monoclonal
Clone: N/A
Isotype: IgG1-lambda
Conjugate: Unconjugated
Physical State: N/A
Buffer: PBS buffer pH7.5
Concentration: N/A
Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.
Alternate Name: NI-0501, emapalumab-lzsg
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.1, 5 The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy.5 As well, emapalumab was given the status of PRIME by the EMA.